Last update: Feb. 12, 2019
Minimal risk for breastfeeding and infant.
Selective ferric iron chelator, orally active, used to treat chronic iron overload in the management of thalassemia and sickle cell anemia, whether transfusion-dependent or not.
The usual oral dose is 20 mg/kg/day taken daily.
Its pharmacokinetic data (very high percentage of plasma protein binding and moderately large volume of distribution) explain the zero transfer to milk observed: no traces of the drug were detected in the breastmilk of a 28-year-old mother with thalassemia major and taking a daily oral dose of 25 mg/kg (Giampetri 2018).
Nor were there growth problems or concentration of serum iron or ferritin in her infant child in any of the determinations during the first month of life (Giampetri 2018).
Until there is further published data on this drug in relation to breastfeeding, it may be advisable to monitor the serum iron level of the infant.
We do not have alternatives for Deferasirox since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.